Once-Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head-to-... (troduction. BYETTA is indicated for use ...)

Once-Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head-to-Head Study

Date:10/31/2007

troduction. BYETTA is indicated for use twice a day in adults with type 2 diabetes who are unsuccessful at controlling their blood sugar levels using common oral diabetes medications.

Once-weekly exenatide uses a proprietary technology for long-acting medications developed by Alkermes. The technology encapsulates active medication into polymer-based microspheres that are injected into the body where they degrade slowly, gradually releasing the drug at a carefully controlled rate.

Study Design

The 30-week, open-label, noninferiority study included 295 subjects with type 2 diabetes who were not achieving adequate glucose control using diet and exercise with or without the use of one or more oral antidiabetic agents. Subjects were randomized to receive subcutaneous injections of either once- weekly exenatide 2.0 milligrams or BYETTA taken twice daily as outlined in the approved label. Subjects in both groups who completed the randomized portion of the study continued in the open-ended portion of the study receiving once- weekly exenatide.

Full study results will be included in future scientific publications.

Webcast Investor Conference Call

Amylin Pharmaceuticals will webcast a conference call to discuss these study results today, Wednesday, October 31 at 8:30 a.m. ET (5:30 a.m. PT). Daniel M. Bradbury, President and Chief Executive Officer of Amylin Pharmaceuticals, will lead the call.

The call will be webcast live through Amylin's corporate website and a recording will be made available following the close of the call. To access the webcast, please log on to http://www.amylin.com approximately fifteen minutes prior to the call to register, download and install any necessary audio software. For those without access to the Internet, the live call may be accessed by phone by calling (866) 356-3095 (domestic) or (617) 597-5391 (international), passcode 19644079. A replay of the ca
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine news :

1. Diabetes Drug, Exenatide, Good For Blood Sugar Levels and Weight Loss
2. Osaka Medical Center study showed 70% of smokers couldn’t qui
3. Women Taking Oestrogen Therapy Showed Reduced Coronary Artery Calcification
4. Link Between Vietnam Service And Prostate Cancer Is Statistically Insignificant
5. Biomarkers Predicting Mortality Found Using Statistical Technique
6. Manmohan Calls for Statistical Reforms in Healthcare and Education
7. Treatment For Sleep Apnea Found To Lower Blood Glucose Levels
8. More soy benefits on blood glucose levels, and cholesterol
9. Lower risk of cardiovascular disease from tight glucose control
10. Glucose may support in Cardiac Arrest
11. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions

Post Your Comments:

Once-Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head-to-...(troduction. BYETTA is indicated for use ...),Health